{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:51:38Z","timestamp":1761238298610,"version":"3.37.3"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2016,6,3]],"date-time":"2016-06-03T00:00:00Z","timestamp":1464912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL096525"],"award-info":[{"award-number":["R01HL096525"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["EY019309"],"award-info":[{"award-number":["EY019309"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["EY022739"],"award-info":[{"award-number":["EY022739"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0155990","type":"journal-article","created":{"date-parts":[[2016,6,3]],"date-time":"2016-06-03T14:00:19Z","timestamp":1464962419000},"page":"e0155990","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["sFlt Multivalent Conjugates Inhibit Angiogenesis and Improve Half-Life In Vivo"],"prefix":"10.1371","volume":"11","author":[{"given":"Eda I.","family":"Altiok","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shane","family":"Browne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Khuc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth P.","family":"Moran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangfang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge L.","family":"Santiago-Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-xing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matilda F.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin E.","family":"Healy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,6,3]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.diabres.2009.10.007","article-title":"Global estimates of the prevalence of diabetes for 2010 and 2030","volume":"87","author":"JE Shaw","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"issue":"13","key":"ref2","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMra1005073","article-title":"Diabetic retinopathy","volume":"366","author":"DA Antonetti","year":"2012","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.2337\/diab.38.10.1203","article-title":"Perspectives in Diabetes Pathogenesis of Diabetic Retinopathy","volume":"38","author":"RL Engerman","year":"1989","journal-title":"Diabetes"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.2337\/diacare.27.2007.S84","article-title":"Retinopathy in Diabetes","volume":"27","author":"D.S. Fong","year":"2004","journal-title":"Diabetes Care"},{"issue":"5","key":"ref5","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1136\/bjo.82.5.561","article-title":"VEGF localisation in diabetic retinopathy","volume":"82","author":"M Boulton","year":"1998","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"ref6","first-page":"106","article-title":"Vascular endothelial growth factor a in intraocular vascular disease","volume":"120","author":"JW Miller","year":"2013","journal-title":"Ophthalmology. Elsevier Inc."},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1350-9462(02)00043-5","article-title":"Vascular endothelial growth factors and angiogenesis in eye disease","volume":"22","author":"A Witmer","year":"2003","journal-title":"Prog Retin Eye Res"},{"issue":"3","key":"ref8","first-page":"434","article-title":"Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye)","volume":"32","author":"MW Stewart","year":"2012","journal-title":"Retina"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/857148","article-title":"A 2-year, phase IV, multicentre, observational study of ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration in routine clinical practice: The EPICOHORT study","volume":"2014","author":"S Pagliarini","year":"2014","journal-title":"J Ophthalmol"},{"issue":"3","key":"ref10","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/IAE.0b013e31827b6324","article-title":"Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study","volume":"33","author":"SY Cohen","year":"2013","journal-title":"Retina"},{"issue":"9","key":"ref11","first-page":"867","article-title":"Characterization of the extracellular domain in vascular endothelial growth factor receptor-1 (Flt-1 tyrosine kinase)","volume":"88","author":"K Tanaka","year":"1997","journal-title":"JpnJCancer Res"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.biomaterials.2016.03.017","article-title":"Multivalent Hyaluronic Acid Bioconjugates Improve sFlt Activity In Vitro","volume":"93","author":"EI Altiok","year":"2016","journal-title":"Biomaterials"},{"issue":"16","key":"ref13","first-page":"10382","article-title":"Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1","volume":"272","author":"B Barleon","year":"1997","journal-title":"JBiolChem"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1089\/ten.tea.2014.0281","article-title":"Multivalent conjugates of sonic hedgehog accelerate diabetic wound healing","volume":"21","author":"BW Han","year":"2015","journal-title":"Tissue Eng Part A"},{"issue":"October","key":"ref15","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/nnano.2013.205","article-title":"Multivalent ligands control stem cell behaviour in vitro and in vivo","volume":"8","author":"A Conway","year":"2013","journal-title":"Nat Nanotechnol. Nature Publishing Group"},{"issue":"4","key":"ref16","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1021\/bc700265k","article-title":"Multivalency of Sonic hedgehog conjugated to linear polymer chains modulates protein potency","volume":"19","author":"ST Wall","year":"2008","journal-title":"Bioconjug Chem"},{"issue":"1","key":"ref17","first-page":"101","article-title":"Oxygen-induced retinopathy in the mouse","volume":"35","author":"LEH Smith","year":"1994","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"10","key":"ref18","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1182\/blood-2008-08-172742","article-title":"Degradation of soluble VEGF receptor-1 by MMP-7 allows VEGF access to endothelial cells","volume":"113","author":"T-K Ito","year":"2009","journal-title":"Blood"},{"issue":"Pt 17","key":"ref19","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1242\/jcs.128033","article-title":"Protective effects of matrix metalloproteinase-12 following corneal injury","volume":"126","author":"MF Chan","year":"2013","journal-title":"J Cell Sci"},{"issue":"3","key":"ref20","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2613.2008.00633.x","article-title":"A critical analysis of current in vitro and in vivo angiogenesis assays","volume":"90","author":"CA Staton","year":"2009","journal-title":"Int J Exp Pathol"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1208\/s12248-010-9183-3","article-title":"Ocular drug delivery","volume":"12","author":"R Gaudana","year":"2010","journal-title":"AAPS J"},{"issue":"2","key":"ref22","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ejpb.2005.01.009","article-title":"Cell culture models of the ocular barriers","volume":"60","author":"M Hornof","year":"2005","journal-title":"Eur J Pharm Biopharm"},{"issue":"6","key":"ref23","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/0039-6257(93)90141-S","article-title":"Minimizing Systemic Absorption of Topically Administered Ophtalmic Drugs","volume":"37","author":"A Urtti","year":"1993","journal-title":"Surv Ophtalmol"},{"issue":"5","key":"ref24","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/IAE.0b013e3181a2f42a","article-title":"Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration","volume":"29","author":"M Abrishami","year":"2009","journal-title":"Retina"},{"issue":"12","key":"ref25","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1023\/A:1007657109012","article-title":"Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys","volume":"17","author":"DW Drolet","year":"2000","journal-title":"Pharm Res"},{"issue":"7","key":"ref26","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00417-010-1315-z","article-title":"A review of clinical trials of anti-VEGF agents for diabetic retinopathy","volume":"248","author":"BP Nicholson","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"ref27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF02482606","article-title":"Oxygen-induced retinopathy in the rat model","volume":"74","author":"B Ricci","year":"1990","journal-title":"Doc Ophthalmol"},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10633-009-9198-1","article-title":"The anatomy of the rat eye with oxygen-induced retinopathy","volume":"120","author":"JD Akula","year":"2010","journal-title":"Doc Ophthalmol"},{"issue":"2","key":"ref29","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1167\/iovs.10-5813","article-title":"Effects of vitreous liquefaction on the intravitreal distribution of sodium fluorescein, fluorescein dextran, and fluorescent microparticles","volume":"52","author":"LE Tan","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"ref30","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1089\/108076801753162807","article-title":"Review: practical issues in intravitreal drug delivery","volume":"17","author":"D Maurice","year":"2001","journal-title":"J Ocul Pharmacol Ther"},{"issue":"12","key":"ref31","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","article-title":"Pharmacokinetics of intravitreal ranibizumab (Lucentis)","volume":"114","author":"SJ Bakri","year":"2007","journal-title":"Ophthalmology"},{"issue":"2","key":"ref32","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1167\/iovs.04-0601","article-title":"Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration","volume":"46","author":"J Gaudreault","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"30","key":"ref33","doi-asserted-by":"crossref","first-page":"6026","DOI":"10.1016\/j.biomaterials.2009.07.024","article-title":"Synthesis, characterization, and preliminary assessment of anti-Flt1 peptide-hyaluronate conjugate for the treatment of corneal neovascularization","volume":"30","author":"EJ Oh","year":"2009","journal-title":"Biomaterials"},{"issue":"11","key":"ref34","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1016\/j.biomaterials.2011.01.003","article-title":"Anti-Flt1 peptide\u2014Hyaluronate conjugate for the treatment of retinal neovascularization and diabetic retinopathy","volume":"32","author":"EJ Oh","year":"2011","journal-title":"Biomaterials. Elsevier Ltd"},{"issue":"3\u20134","key":"ref35","first-page":"135","article-title":"Current and future ophthalmic drug delivery systems. A shift to the posterior segment","volume":"13","author":"EM Del Amo","year":"2008","journal-title":"Drug Discov Today"},{"issue":"2","key":"ref36","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jconrel.2012.01.019","article-title":"Liposomes for intravitreal drug delivery: a state of the art","volume":"161","author":"A Bochot","year":"2012","journal-title":"J Control Release. Elsevier B.V."},{"issue":"3","key":"ref37","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000209665","article-title":"Novel drug delivery systems for retinal diseases. A review","volume":"41","author":"SS Lee","year":"2009","journal-title":"Ophthalmic Res"},{"issue":"5","key":"ref38","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin)","volume":"114","author":"SJ Bakri","year":"2007","journal-title":"Ophthalmology"},{"issue":"6","key":"ref39","doi-asserted-by":"crossref","first-page":"303","DOI":"10.4239\/wjd.v4.i6.303","article-title":"Vascular endothelial growth factor trap-eye (Aflibercept) for the management of diabetic macular edema","volume":"4","author":"A Moradi","year":"2013","journal-title":"World J Diabetes"},{"issue":"1","key":"ref40","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4081\/eye.2011.e5","article-title":"What are the half-lives of ranibizumab and aflibercept (VEGF Trap-eye) in human eyes? Calculations with a mathematical model","volume":"1","author":"MW Stewart","year":"2011","journal-title":"Eye Reports"},{"issue":"9","key":"ref41","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1517\/17425247.5.9.1039","article-title":"Iluvien: a new sustained delivery technology for posterior eye disease","volume":"5","author":"FE Kane","year":"2008","journal-title":"Expert Opin Drug Deliv"},{"key":"ref42","article-title":"Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema","author":"DS Boyer","year":"2014","journal-title":"Ophthalmology"},{"issue":"3","key":"ref43","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1345\/aph.1H540","article-title":"Retisert: is the new advance in treatment of uveitis a good one?","volume":"41","author":"DA Mohammad","year":"2007","journal-title":"Ann Pharmacother"},{"issue":"3\u20134","key":"ref44","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.drudis.2007.10.021","article-title":"Nanotechnology in ocular drug delivery","volume":"13","author":"SK Sahoo","year":"2008","journal-title":"Drug Discov Today"},{"issue":"5","key":"ref45","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0142-9612(00)00193-9","article-title":"Peptide and protein PEGylation","volume":"22","author":"FM Veronese","year":"2001","journal-title":"Biomaterials"},{"issue":"10","key":"ref46","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1002\/jps.21278","article-title":"The pharmacology of PEGylation: Balancing PD with PK to generate novel therapeutics","volume":"97","author":"SC Fishburn","year":"2010","journal-title":"J Pharm Sci"},{"issue":"2","key":"ref47","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrd1955","article-title":"Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease","volume":"5","author":"EWM Ng","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"ref48","doi-asserted-by":"crossref","first-page":"397","DOI":"10.17221\/1930-VETMED","article-title":"Hyaluronic acid (hyaluronan): a review","volume":"2008","author":"J Necas","year":"2008","journal-title":"Vet Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0155990","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T03:21:11Z","timestamp":1567999271000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0155990"}},"subtitle":[],"editor":[{"given":"Guei-Sheung","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,6,3]]},"references-count":48,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,6,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0155990","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2016,6,3]]}}}